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•Systematic review and meta-analysis•

Electroconvulsive therapy for agitation in schizophrenia: metaanalysis of randomized controlled trials
Xiaojing GU1#, Wei ZHENG2#, Tong GUO3, Gabor S. UNGVARI4,5, Helen F.K. CHIU6, Xiaolan CAO6, 7, Carl D’ARCY8,
Xiangfei MENG9, Yuping NING1*, Yutao XIANG10*

Background: Agitation poses a significant challenge in the treatment of schizophrenia. Electroconvulsive
therapy (ECT) is a fast, effective and safe treatment for a variety of psychiatric disorders, but no meta-analysis
of ECT treatment for agitation in schizophrenia has yet been reported.
Aims: To systematically evaluate the efficacy and safety of ECT alone or ECT-antipsychotics (APs) combination
for agitation in schizophrenia.
Methods: Systematic literature search of randomized controlled trials (RCTs) was performed. Two
independent evaluators selected studies, extracted data about outcomes and safety with available
data, conducted quality assessment and data synthesis. The Grades of Recommendation, Assessment,
Development, and Evaluation (GRADE) was used to judge the level of the overall evidence of main outcomes.
Results: Seven RCTs from China, including ECT alone (4 RCTs with 5 treatment arms, n=240) and ECT-APs
combination (3 RCTs, n=240), were identified. Participants in the studies were on average 34.3(4.5) years of
age and lasted an average of 4.3(3.1) weeks of treatment duration. All 7 RCTs were non-blinded, and were
rated as low quality based on Jadad scale. Meta-analysis of the pooled sample found no significant difference
in the improvement of the agitation sub-score of the Positive and Negative Syndrome Scale (PANSS) when
ECT alone (weighted mean difference=-0.90, (95% confidence interval (CI): -2.91, 1.11), p=0.38) or ECT-APs
combination (WMD=-1.34, (95%CI: -4.07, 1.39), p=0.33) compared with APs monotherapy. However, ECT
alone was superior to APs monotherapy regarding PANSS total score (WMD=-7.13, I2=0%, p=0.004) and its
excitement sub-score (WMD=-1.97, p<0.0001) as well as the PANSS total score at 14 days (WMD=-7.13,
I2=0%, p=0.004) and its excitement sub-score at 7 and 14 days (WMD=-1.97 to -1.92, p=0.002 to 0.0001) after
ECT. The ECT-APs combination was superior to APs monotherapy with respect to the PANSS total score at
treatment endpoint (WMD=-10.40, p=0.03) and 7 days (WMD=-5.01, p=0.02). Headache ( number-neededto-harm (NNH)=3, 95%CI=2-4) was more frequent in the ECT alone group compared to AP monotherapy.
According to the GRADE approach, the evidence levels of main outcomes were rated as ‘‘very low’’ (37.5%)
and “low” (50%).
Conclusion: Pooling of the data based on 7 RCTs from China found no advantage of ECT alone or ECT-APs
combination in the treatment of agitation related outcomes in schizophrenia patients. However, ECT alone or
ECT-APs combination were associated with significant reduction in the PANSS total score. High-quality RCTs
are needed to confirm the current interpretations.
Review registration number: CRD42014006689
Key words: Electroconvulsive therapy; agitation; schizophrenia; headache, meta-analysis
[Shanghai Arch Psychiatry. 2017; 29(1): 1-14. doi: http://dx.doi.org/111919/j.issn.1002-0829.217003]
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1. Introduction
Agitation, excessive motor and/or verbal activity,
characterized by excitement, restlessness, and psychic
and motor tension, is common in patients with
schizophrenia. Agitation can escalate into aggressive
behavior leading to high risk of injury for patients,
relatives or staff.[1-3] Furthermore, agitation increases the
frequency of patient emergency department visits with
further negative consequences.[4]
In order to minimize the risk posed to self or
others, agitated patients should be managed, first
and preferably by non-pharmacological interventions
such as environmental and behavioral modification,
and secondly by pharmacological agents.[3-5] However,
in most cases the management of agitation largely
depends on pharmacological agents, [6] mainly
benzodiazepines and antipsychotics (APs) with their
well-known adverse effects particularly if they are
administered repeatedly.[1,3]
Electroconvulsive therapy (ECT) is a fast, effective
and safe treatment for a variety of psychiatric disorders.
[7]
Use of ECT for acute or even prolonged agitation has
received scant attention in contemporary literature and
it appears that ECT is hardly ever used for this purpose
in developed countries. However, ECT remains an option
for agitation or aggression in China and developing
countries. [8] There have been a number of studies
published in China, including randomized controlled
trials (RCTs)[9-15] to compare the efficacy of ECT alone
or the ECT-AP combinations to AP monotherapy with
conflicting results.
To the best of our knowledge, no systematic review
or meta-analysis of ECT treatment for agitation in
schizophrenia has been published. This was the impetus
for this meta-analysis concerning the efficacy and safety
of ECT treatment for agitation in schizophrenia.
2. Methods
2.1 Selection of studies
According to PICOS acronym, the inclusion criteria
were: Participants (P): adult schizophrenia patients
(≥18 years) with agitation. Intervention (I): ECT
alone and ECT-AP combination. Comparison (C): AP
monotherapy. Outcomes (O): primary outcomes were
the improvement of agitation related outcomes at lastobservation-carried-forward (LOCF) study endpoint
measured by the Positive and Negative Syndrome Scale
(PANSS),[16] Brief Psychiatric Rating Scale (BPRS),[17] and
any other scales or sub-scales or item for agitation: 1)
total psychopathology scores, 2) the excitement subscores, and 3) the agitation sub-scores. Key secondary
outcomes included early symptomatic improvement (at
1, 3, 7, and 14 days), rate of all-cause discontinuation
and patient-reported adverse events. Study design (S):
RCT with available data. The exclusion criteria were
case series, non-randomized studies, and non-original
research (reviews and meta-analyses).
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2.2 Search strategy
English databases (PubMed, PsycINFO, and Cochrane
Library) and Chinese databases (WanFang Database,
Chinese Biomedical Database and China Journal
Net) were searched, from their inception until Feb
3, 2017 using the following search terms: (1) English
databases: (ECT OR Electric Convulsive Therap* OR
Therap*, Electric Convulsive OR Electroshock Therap*
OR Convulsive Therap*, Electric) OR Electroconvulsive
Therapy OR Electroconvulsive Therapies OR Therap*,
Electroconvulsive OR Electric Shock Therap* OR
Shock Therap*, Electric OR Therap*, Electric Shock OR
Therap*, Electroshock) AND (schizoaffective disorder
OR schizophreniform OR Schizophrenic Disorder OR
Disorder, Schizophrenic OR Schizophrenic Disorders OR
Schizophrenia OR Dementia Praecox) AND (agitation OR
exciting OR aggression); (2) Chinese databases: ( 电休克
OR 电抽搐 OR ECT OR MECT OR 电痉挛 ) AND ( 激越
OR 攻击 OR 兴奋）AND 随机 AND ( 精神分裂症 OR
精神分裂 ). The search was supplemented by using the
“related article” function. Hand-searched reference lists
from relevant review articles for additional studies were
hand-searched and authors contacted for unpublished
data.
2.3 Data extraction
Two independent evaluators (GXJ and ZW) selected
studies, extracted data, conducted quality assessment
and data synthesis. Any inconsistencies were resolved
by discussion to reach consensus or involvement of a
third reviewer (XYT).
2.4 Data synthesis and statistical analyses
Clinical outcomes were based on intent-to-treat (ITT)
analysis, if available. The meta-analysis was performed
using Review Manager (version 5.3) according to the
recommendations of the Cochrane Collaboration.[18] To
combine studies, the random effects model [19] was used
in all cases. For continuous data and dichotomous data,
weighted mean differences (WMDs) associated with
their 95% confidence intervals (CIs) and risk ratio (RR)
±95% CIs were calculated, respectively. We reported
the number-needed-to-treat (NNT) or number-neededto-harm (NNH) calculated by dividing 1 by the risk
difference as soon as RR was significant. One study
[11]
from the ‘ECT alone’ group had three study arms.
According to the methodology of prior meta-analysis,[20]
we should include each of the 2 ECT arms separately
in one RCT [11] with 3 treatment arms. Furthermore,
the APs monotherapy arm was included twice in the
analysis, but half of all patients were randomized to
each AP arm in order not to inflate the number of
patients in the APs monotherapy arm.
In case of I2≥50% for the effect of primary outcome
on the PANSS total score, a sensitive analysis was
conducted by excluding one outlying study [15] with
an outlying effect size (ES) of less than -1.24 (i.e.,
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more than 1.24 standard deviation superiority of ECTAP combination) in the ‘ECT-AP combination’ group.
Furthermore, subgroup and meta-regression analyses
were conducted to detect the sources of heterogeneity,
if possible. Publication bias was assessed using funnel
plots and Egger’s test.[21] All statistical differences were
considered significant when p<0.05.
2.5 Assessment of study quality
The Cochrane risk of bias [18] was used to assess the
quality of each study. Furthermore, the quality of
each study was also assessed with the Jadad scale
that assesses study quality on a 5-point scale along
the following five domains: “randomization,” “double
blinding,” “description withdrawals and dropouts,”
“generation of random numbers,” and “allocation
concealment”.[22] The criteria of high and low quality
were defined as Jadad score ≥4 and <4, respectively.
2.6 Clinical evidence recommendation
The grading of recommendations assessment,
development, and evaluation (GRADE) system [23]
was used to judge the quality of clinical evidence
recommendations of the meta-analytic results of ECT
for agitation in schizophrenia.
3. Results
3.1 Results of the search
Altogether 133 potentially relevant articles from English
(n=96) and Chinese databases (n=37) were identified;
duplication excluded 14 studies. Of the remaining 119
entries, 112 were determined to be irrelevant after
review of the titles and abstracts, a further 7 were
removed on the basis of full text review. Finally, 7 RCTs
with 8 treatment arms met the selection criteria for the
meta-analysis (Figure 1).
3.2 The characteristics of included studies
The seven RCTs lasted an average of 4.3(3.1) weeks
(range: 2-8 weeks; median: 2 weeks). The total number
of participants in all the studies was 480 (range: 30100, median: 60). All the RCTs that met our inclusion
and exclusion criteria were thus included in the metaanalysis had been conducted in China. Aggregating data
across all the reviewed trials: there were 240 patients
in ECT monotherapy vs. AP monotherapy (n=135 vs.
n=105) comparison and 240 patients in the ECT-AP vs.
AP monotherapy (n=120 vs. n=120) comparison (Table
1); patients were on average 34.3(4.5) years old (range:
31.9-43.5 years; median: 32.5 years) in 6 RCTs with
available data; 57.6(14.2)% were males (range: 40.0%80.0%; median: 56.7%); and the mean illness duration
with available data (6 RCTs) was 2.7(2.7) years (range:
0.02-6.1 years; median: 2.2 years).
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3.3 Assessment of risk of bias and quality assessment
The Cochrane risk of bias was presented in Table 2.
85.7% (6/7) RCTs only mentioned “random” assignment,
lacking a detailed description of the method of
randomizing and thus were rated as unclear. However,
only one RCT [13] using random assignment according to
the random number table was rated as low risk. Given
that all included studies were open label, the allocation
bias, performance bias, and detection bias were rated
as high risk. None of the included RCTs presented
the study registration materials, which limited us to
determine whether or not there was selective reporting
(i.e., reporting bias). Furthermore, it was impossible
to judge the other types of biases (e.g., drug company
sponsorship of the study) due to lack of available
evidence. Overall, 7 included RCTs suffered from high
risk of bias and were considered as relatively lowquality studies. The Jadad score was 2.0(0.6) (range=1-3,
median=2) (Table 1). All RCTs were rated as low quality
(Jadad score < 4). Due to pooling of data, less than 3
RCTs with 4 treatment arms were in all forest plots,
thus funnel plot analysis to show the presence of risk of
publication bias could not be conducted.
3.4 The improvement of agitation related outcomes
There were differences between the ECT alone vs AP (4
RCTs with 5 treatment arms) and ECT-AP vs AP (3 RCTs)
groups. Moreover, the improvement of agitation related
outcomes were measured using PANSS in all included
RCTs.
ECT alone vs AP: ECT alone was superior to AP
monotherapy with respect to PANSS total score (WMD=7.13, (95%CI: -11.99, -2.27), I2=0%, p=0.004, Figure
2) and excitement sub-score (WMD=-1.97, (95%CI:
-2.87, -1.08), I2=0%, p<0.0001, Figure 2), but not in
the agitation sub-score (WMD=-0.90, p=0.38); ECT
alone was superior to AP monotherapy in PANSS total
score at 14 days (WMD:-7.13 (95%CI:-11.99, -2.27),
p=0.004; I2=0%, Supplemental Figure 1), but not at 1
and 7 days (WMD:-5.23 to -7.13 (95%CI:-16.86, 4.25),
p=0.06 to 0.24; I2=0% to 77%, Supplemental Figure 1).
Furthermore, subgroup and meta-regression analyses
could not be performed due to the limited number of
RCTs.
Furthermore, ECT alone was superior to AP
monotherapy in PANSS excitement sub-score at 7 and
14 days (WMD:-1.97 to -1.92 (95%CI:-3.14, -0.71),
p=0.002 to 0.0001; I2=0%, Supplemental Figure 2), but
not at 1 day after ECT treatment (WMD:-1.92 (95%CI:4.00, 0.17), p=0.07; I2=35%, Supplemental Figure 2).
Among the ECT alone studies one RCT [10] used Clinical
Global Impression (CGI) and found an advantageous
improvement of psychiatric symptoms in the ECT group
at 7 and 14 days.
ECT plus AP vs AP: Regarding the PANSS total
score, the ECT-AP combination was superior to AP
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Figure 1. Identification of included studies
133 articles published before Feb 3, 2017 were identified using a standard search strategy and other sources (see
methods section):
•
17 from China Journal Net
•
20 from WanFang Database
•
0 from Chinese Biomedical database
•
43 from PubMed
•
50 from PsycINFO
•
3 from Cochrane Library databases

14 duplicates removed

119 unduplicated studies; 24 published in Chinese, 95 in English
105 articles excluded based on title and abstract
14 full-text articles assessed for eligibility
7 full-text articles excluded:
•
1 duplicate publication
•
1 lack of specific diagnosis
•
2 using intramuscular injection clonazepam
•
1 risperidone combined with ECT versus Haloperidol
•
2 antipsychotic combined with ECT versus two different
antipsychotics combination

7 studies included in qualitative synthesis

7 studies with 8 treatment arms included in qualitative synthesis

monotherapy (WMD=-10.40, (95%CI: -19.67, -1.12),
I2=93%, p=0.03, Figure 3), but not in the excitement and
agitation sub-scores (WMD=-1.06 to -1.34, p=0.33 to
0.37). The significant difference between the two groups
in the PANSS total score disappeared after one outlying
study [15] was removed (WMD:-4.23 (95%CI:-8.89, 0.43),
p=0.08; I2=76%). Furthermore, subgroup and metaregression analyses could not be performed due to the
limited number of RCTs.
Furthermore, adding ECT to AP was superior to
AP monotherapy at 7 days for the PANSS total score
(WMD=-5.01, (95%CI: -9.37, -0.66), I2=14%, p=0.02,
Figure 4), but not to PANSS total score (p=0.15),
excitement (p=0.35) and agitation sub-scores (p=0.44)
at 14 days (Figures 4).

3.5 Side effects and discontinuation rate
The Treatment Emergent Symptom Scale (TESS) was
generally used to assess adverse drug reactions (ADRs)
in these RCTs however such data were not available in
1 RCT (Table 1). None of the included RCTs reported the
rate or cause of treatment discontinuation.
ECT alone vs APs: Headache (p=0.0001, NNH=3,
95%CI=2-4) was the only ADRs more frequent in
the ECT alone group compared to AP monotherapy
(Supplemental Figure 3). There was significantly
less akathisia (p=0.02, NNH=8, 95%CI=5-17) and
electrocardiogram changes (p=0.05) with borderline
significance in the ECT alone group compared to the AP
group. Meta-analysis of uroclepsia, weight gain, upper
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Table 1. Characteristics of the RCTs
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Table 2. Evaluation of risk of bias in the seven included studies
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Figure 2. ECT alone for agitation in schizophrenia: forest plot for the Positive and Negative Syndrome Scale
(PANSS) total score and its PANSS excitement and agitation sub-scores at endpoint
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Figure 3. Add-on ECT to antipsychotics for agitation in schizophrenia: forest plot for the Positive and Negative
Syndrome Scale (PANSS) total score and its excitement and agitation sub-scores at endpoint

respiratory infections, tremor, dry mouth, insomnia, and
electroencephalography changes did not differ between
the groups (Supplemental Figure 3).
ECT plus AP vs AP: Only two RCTs [9,13] reported the
ADRs without meta-analyzable data.
3.6 Clinical evidence recommendation
Clinical evidence recommendation of the main metaanalytic outcomes based on the GRADE approach
showed some limitations of risk of bias, inconsistency
and publishing bias, and no obvious indirectness or
imprecision. According to the above assessments, the
quality of evidence of 8 outcomes presented in Table 3
and ranged from ‘‘very low’’ (37.5%), “low” (50%), to
‘‘high’’ (12.5%).
4. Discussion
4.1 Main findings
Despite a systematic literature search in both English
and Chinese-language databases, we only identified 7

RCTs with 8 treatment arms that examined the efficacy
and safety of using ECT for the treatment of agitation
in 480 patients with schizophrenia who are currently
using APs. All included RCTs were open label and the
assessment of outcomes was not blinded in all trials.
Furthermore, the quality of all included RCTs was rated
as ‘low quality’ based on Jadad scale. Overall, the
results suggest that both ECT alone and the ECT-AP
combination over 2 to 8 weeks had superior efficacy to
AP monotherapy regarding the reduction in PANSS total
score, but not in the agitation sub-score. ECT and ECTAP combination were both safe and well tolerated. The
reduction in the total PANSS score with ECT alone was
superior to AP monotherapy as early as at 1 day with
a moderate effect size of -0.52, which increased to a
relatively larger effect size of -0.60 after 14 days. The
ECT-AP combinations were significantly superior to AP
monotherapy with respect to PANSS total score at 7 days
with a small effect size of -0.36. However, 35 patients
reported headache (38.9% vs. 0% on APs monotherapy,
NNH=3), which was significantly more common in the
ECT alone group. These adverse effects were transient
and mild.[10,11]
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Figure 4. Add-on ECT to antipsychotics for agitation in schizophrenia: forest plot for the Positive and Negative
Syndrome Scale (PANSS) total score at 7 and 14 days as well as PANSS agitation and excitement subscore at 14 days
Secondary outcomes
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Mean Difference
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4.2 PANSS Total Score (14 days)
Pan 2015
68.2 22.6 50 75.3 25.1
Peng 2014

23.84 7.55

40 25.62 8.15

50 30.6%
40

35.0%

-7.10 [-16.46, 2.26]
-1.78 [-5.22, 1.66]

Yang 2005
59.38 8.66 30 80.06 9.51 30 34.4% -20.68 [-25.28, -16.08]
Subtotal (95% CI)
120
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Heterogeneity: Tau² = 134.46; Chi² = 41.62, df = 2 (P < 0.00001); I² = 95%
Test for overall effect: Z = 1.43 (P = 0.15)

4.3 PANSS Excitement Sub-Score (14 days)
Peng 2014
1.07 0.23 40 1.02 0.44
Yang 2005
9.67 3.73 30 13.82 3.64
Subtotal (95% CI)

70

40 52.5%
30 47.5%

70 100.0%

0.05 [-0.10, 0.20]
-4.15 [-6.01, -2.29]
-1.94 [-6.05, 2.17]

Heterogeneity: Tau² = 8.36; Chi² = 19.35, df = 1 (P < 0.0001); I² = 95%
Test for overall effect: Z = 0.93 (P = 0.35)
4.4 PANSS Agitation Sub-sore (14 days)

1.01 0.18 40 1.03 0.49 40 64.2%
Peng 2014
-0.02 [-0.18, 0.14]
8.24 2.61 30 9.81 3.73 30 35.8%
Yang 2005
-1.57 [-3.20, 0.06]
Subtotal (95% CI)
70
70 100.0% -0.57 [-2.03, 0.88]
Heterogeneity: Tau² = 0.85; Chi² = 3.44, df = 1 (P = 0.06); I² = 71%
Test for overall effect: Z = 0.77 (P = 0.44)
-20

4.2 Limitations
Several limitations need to be acknowledged. First, 7
RCTs (100%) reviewed were rated as low quality and
the strength of the evidence for 87.5% outcomes was
rated as “very low” or “low” according to the GRADE
approach. However, strong recommendations does not
necessarily imply high quality evidence and low quality
evidence can still result in strong recommendations.[23]
Further, the RCTs were inconsistent in their methodology
with respect to sampling and the delivery of ECT and the
type and dose of antipsychotic medications. Subgroup
analyses and meta-regression cannot be employed to
lessen the heterogeneity of primary outcomes. Second,
data regarding the cognitive effects of ECT were not
systematically assessed in the included studies. In
addition, agitation, the target symptom in this study,
was evaluated with a single item in the PANSS, rather
than with a standardized rating scale. Furthermore,
some more variables potentially associated with
agitation, such as the quality of care and patients’

-10

0

10

20

ECT is better Control is better

education, were not assessed in included studies. Third,
treatment adherence was not routinely assessed or
reported. In particular, the ECT dose-response effects
on agitation when used as monotherapy or/and cotreatment in agitation patients with schizophrenia,
definitely needs to be more fully evaluated. Finally, all
studies were conducted in China thus the findings need
to be replicated in other countries.
4.3 Implications
Although this paper included 7 low quality RCTs with
small samples and the methodological limitations [23]
identified, the thorough methodology of this metaanalysis included the assessment of quality using
the Cochrane risk of bias, [18] Jadad scale [22] , and
GRADE system.[23] The heterogeneity of PANSS total
score assessed by I 2 decreased from 93% to 76%
after removing one outlying study; [15] in addition,
the significance disappeared, which could be due
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Table 3. GRADE Analyses for main primary and secondary outcomes: ECT for agitation in schizophrenia
Outcomes

of
N (arms) Risk
bias Inconsistency Indirectness

Imprecision

Publication Large Overall quality
bias
effect of evidencea

ECT alone vs. APs
90 (2) Seriousb

No

No

No

Seriousd

No

Low

PANSS excitement 180 (4) Seriousb
sub-score

No

No

No

Seriousd

No

Low

PANSS agitation
sub-score

30 (1) Seriousb

No

No

No

Seriousd

No

Low

Headache

180 (3) Seriousb

No

No

No

Seriousd

Very
largee

High

Akathisia

180 (3) Seriousb

No

No

No

Seriousd

No

Low

240 (3) Seriousb

Seriousc

No

No

Seriousd

No

Very Low

PANSS excitement 140 (2) Seriousb
sub-score

Seriousc

No

No

Seriousd

No

Very Low

PANSS agitation
sub-score

Seriousc

No

No

Seriousd

No

Very Low

PANSS total score

ECT+ APs vs. APs
PANSS total score

140 (2) Seriousb

APs = antipsychotics; ECT = Electroconvulsive therapy; GRADE = grading of recommendations assessment, development, and evaluation;
PANSS = Positive and Negative Syndrome Scale
a
GRADE Working Group grades of evidence: High quality=further research is very unlikely to change our confidence in the estimate of
effect. Moderate quality=further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate. Low quality=further research is very likely to have an important impact on our confidence in the estimate of effect
and is likely to change the estimate. Very low quality=we are very uncertain about the estimate.
b
All studies reported as having a serious bias used a open label method, only mentioned random allocation without describing the
method and withdrawal from the study.
c
All studies reported as having a serious inconsistency had I2> 50%.
d
For continuous outcomes, N < 400; For dichotomous outcomes, N<300.
e
The results of meta-analytic outcomes: RR>5 or <0.2

to the decreased sample size thereby reducing the
power detecting significant results. The previous
meta-analyses[24-25] supported our interpretation that
adjunctive ECT can be an efficacious treatment for
improving total psychopathology in schizophrenia
patients. Agitation poses a significant challenge in the
treatment of schizophrenia.[1] However, the current
meta-analysis of 7 relatively low quality RCTs showed
that both ECT alone and the ECT-AP combination are
ineffective treatments for agitation in 480 Chinese
schizophrenia patients. This meta-analysis indicates
that other symptoms (e.g. hallucination, delusion, etc.)
maybe respond better to ECT when compared with
agitation related outcomes in schizophrenia patients.
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电休克治疗用于精神分裂症的激越症状：随机对照试验的 meta 分析
顾小静，郑伟，郭彤，Gabor S. Ungvari，Helen F.K. Chiu，操小兰，Carl D’Arcy，孟祥飞，宁玉萍，项玉涛

背景：躁动在精神分裂症治疗中是一个重大挑战。电
休克疗法（ECT）对各种精神疾病是一种快速、有效、
和安全的治疗，但 ECT 对精神分裂症的躁动治疗的相
关 meta 分析还尚未报道。
目标：系统地评估单一使用 ECT 或 ECT 合并使用其他
抗精神病药物（APs）的对精神分裂症的躁动治疗的有
效性和安全性。
方法：进行随机对照试验（RCT）的系统文献搜索。
两名独立评估者筛选研究、提取结果数据与现有数据
的安全性、进行质量评估和数据合成。采用建议、评估、
开发、和评价的工作组等级（GRADE）来判断主要成
果的证据的总体水平。
结果：一共确定了中国有七个 RCTs，包括 ECT 单一
使用（4 个 RCTs 有 5 个治疗组，n = 240）和 ECT-APs
合并使用（3 个 RCTs，n = 240）。研究对象平均年龄
34.3（4.5）岁，平均治疗时间为 4.3（3.1）周。所有 7
个 RCTs 非盲法，并且根据 Jadad 量表 7 项 RCTs 均被评
为低质量。样本的 Meta 分析发现与 APs 单一治疗相比，
单一使用 ECT 或 ECT-APs 合并使用阳性和阴性症状量
表（PANSS）的躁动子因子评分改善均无显著性差异（ECT
单一使用 : weighted mean difference（WMD）=-0.90,
95% confidence interval (CI): (-2.91, 1.11), p=0.38; ECT-APs

合并使用：WMD=-1.34, (95%CI: -4.07, 1.39), p=0.33）。
然而，PANSS 总分（WMD=-7.13, I2=0%, p=0.004）和
兴奋子因子评分（WMD=-1.97, p<0.0001）、ECT 治疗
14 天后的 PANSS 总分（WMD=-7.13, I2=0%, p=0.004）
和第 7 天和第 14 天的兴奋子因子评分（WMD=-1.97
to -1.92, p=0.002 to 0.0001）均显示单一使用 ECT 优
于 APs 单一治疗。ECT-APs 合并治疗结束时（WMD=10.40, p=0.03）和治疗后 7 天（WMD=-5.01, p=0.02）的
PANSS 总分显示均优于 APs 单药治疗。头痛（p=0.0001,
number-needed-to-harm (NNH)=3, 95%CI=2-4）是唯一
的 ECT 单一治疗后不良反应，并且 ECT 单一治疗组比
APs 单药治疗发生的更频繁。根据 GRADE 方法，主要
结果的证据水平被评为 “ 非常低 ”（37.5%）和 “ 低 ”
（50%）。

结论：基于中国 7 个 RCTs 合并的数据发现 ECT 单一治
疗或 ECT-APs 合并治疗在精神分裂症患者的躁动治疗
中并没有优势。然而，ECT 单一治疗或 ECT-APs 合并治
疗均与 PANSS 总分减低显著有关。需要高质量的 RCTs
验证目前的解释。
关键词：电休克治疗；躁动；精神分裂症；头痛，
meta 分析
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Supplemental Figure 1. ECT alone for agitation in schizophrenia: forest plot for the Positive and Negative
Syndrome Scale (PANSS) total score at 1, 7, and 14 days
Secondary outcomes

Notice for soliciting papers for the 14th academic conference of the Chinese Society of
Neuroscience & Psychiatry (CSNP)
“The 14th annual academic conference of the Chinese Society of Neuroscience & Psychiatry”, which is hosted by
CSNP, and undertaken by Mental Health Center of Shanghai Jiao Tong University’s medical school and Shandong
Mental Health Center, will be held in the Luneng Hilton Hotel in Jinan, Shandong, from 29th June to 1st July, 2017.
The present society welcomes paper submissions and conference participations. The conference affair group
accepts abstracts (objectives, methods, results and conclusions) under 1000 words. The website used for paper
submissions and registrations is http://61.147.124.137:8088/2017/default.aspx. The academic committee of this
conference will review papers and select high quality reports for presentation at the conference. We look forward to
your participation and support! The deadline for paper submission is 1st June, 2017.
We welcome colleagues from all over China and abroad to participate in this conference held in scenic Jinan. We
are looking forward to a lively discussion on developments in the field.
Dates: 29th June to 1st July, 2017 (check in on 29th June)
Address: Luneng Hilton Hotel in Jinan, Shandong, No.2888 South Erhuan Lu, Central District in Jinan
Cost arrangement: The registration fee, travel fee and accommodation fee are at your own expense. The
registration fee is 1000 yuan (Shandong representatives and graduate students with student IDs can pay half of
the registration fee). The accommodation fee from 30th June to 1st July 2017 is 500 yuan per standard room.
Contact: Ruizhi Mao 18221768225
E-mail：csnpmeeting@163.com
Chinese Society of Neuroscience & Psychiatry
4th February 2017
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Supplemental Figure 2. ECT alone for agitation in schizophrenia: forest plot for the Positive and Negative
Syndrome Scale (PANSS) excitement sub-score at 1, 7, and 14 days
Secondary

Erratum
Li HB, Wang Y, Jiang J, Li W, Li CB. Effects of transcranial direct current stimulation (tDCS) for auditory hallucinations:
A systematic review. Shanghai Arch Psychiatry. 2016; 28(6):301-308. doi: http://dx.doi.org/10.11919/
j.issn.1002-0829.216121
In the Figure 1 (identification of included studies) of the paper, the number in the first box “304 potential
articles published before 13 February 2016 were identified…” should be “432 potential articles published
before 13 February 2016 were identified…”. This change was been made to the online version on the
Shanghai Archives of Psychiatry website as of 10 Jan, 2017.
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Supplemental Figure 3. ECT alone for agitation in schizophrenia: forest plot for adverse events
Secondary outcomes

ECT
Events Total

Control
Events Total

Weight

3.1 Headache
32.8%
30
0
30
8
Guo 2009
33.6%
30
0
30
14
Shen 2011a
33.5%
30
0
30
13
Shen 2011b
90 100.0%
90
Subtotal (95% CI)
0
35
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.08, df = 2 (P = 0.96); I² = 0%
Test for overall effect: Z = 3.86 (P = 0.0001)
3.2 Akathisia
36.3%
30
8
30
0
Guo 2009
31.9%
30
2
30
0
Shen 2011a
31.9%
30
2
30
0
Shen 2011b
90 100.0%
90
Subtotal (95% CI)
12
0
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.49, df = 2 (P = 0.78); I² = 0%
Test for overall effect: Z = 2.38 (P = 0.02)
3.3 Electrocardiogram changes
80.5%
30
19
30
11
Li 2015
19.5%
15
5
15
4
Yuan 2012
45 100.0%
45
Subtotal (95% CI)
24
15
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.27, df = 1 (P = 0.60); I² = 0%
Test for overall effect: Z = 1.94 (P = 0.05)
3.4 Uroclepsia
55.5%
30
0
30
6
Shen 2011a
44.5%
30
0
30
1
Shen 2011b
60 100.0%
60
Subtotal (95% CI)
0
7
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.48, df = 1 (P = 0.49); I² = 0%
Test for overall effect: Z = 1.78 (P = 0.08)
3.5 Weight Gain
50.0%
30
1
30
0
Shen 2011a
50.0%
30
1
30
0
Shen 2011b
60 100.0%
60
Subtotal (95% CI)
2
0
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)
3.6 Upper Respiratory Infection
50.0%
30
1
30
0
Shen 2011a
50.0%
30
1
30
0
Shen 2011b
60 100.0%
60
Subtotal (95% CI)
2
0
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)
3.7 Tremor
33.4%
30
13
30
0
Guo 2009
33.3%
30
0
30
10
Shen 2011a
33.3%
30
0
30
7
Shen 2011b
90 100.0%
90
Subtotal (95% CI)
13
17
Total events
Heterogeneity: Tau² = 11.23; Chi² = 13.03, df = 2 (P = 0.001); I² = 85%
Test for overall effect: Z = 0.39 (P = 0.70)
3.8 Dry mouth
50.0%
30
1
30
0
Shen 2011a
50.0%
30
1
30
0
Shen 2011b
60 100.0%
60
Subtotal (95% CI)
2
0
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)
3.9 Insomnia
50.0%
30
1
30
0
Shen 2011a
50.0%
30
1
30
0
Shen 2011b
60 100.0%
60
Subtotal (95% CI)
2
0
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)
3.10 Electroencephalogram changes
50.1%
30
25
30
12
Li 2015
49.9%
15
10
15
11
Yuan 2012
45 100.0%
45
Subtotal (95% CI)
35
23
Total events
Heterogeneity: Tau² = 0.31; Chi² = 6.35, df = 1 (P = 0.01); I² = 84%
Test for overall effect: Z = 0.75 (P = 0.45)
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